Creabilis rounds up $30M

CompanyAmount/RoundLead InvestorsDescription

Creabilis Therapeutics
Sofinnova Partners

The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease.

IRX Therapeutics
New York
Existing investors

The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment.

Inimex Pharmaceuticals
Morningside Venture Investments

The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models.

Creabilis rounds up $30M